Protective anti-tumor vaccination against glioblastoma expressing the MHC class II transactivator CIITA

Glioblastoma is the most malignant tumor of the central nervous system. Current treatments based on surgery, chemotherapy, and radiotherapy, and more recently on selected immunological approaches, unfortunately produce dismal outcomes, and less than 2% of patients survive after 5 years. Thus, there...

Descripción completa

Detalles Bibliográficos
Autores principales: Celesti, Fabrizio, Gatta, Andrea, Shallak, Mariam, Chiaravalli, Anna Maria, Cerati, Michele, Sessa, Fausto, Accolla, Roberto S., Forlani, Greta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040613/
https://www.ncbi.nlm.nih.gov/pubmed/36993983
http://dx.doi.org/10.3389/fimmu.2023.1133177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040613/
https://www.ncbi.nlm.nih.gov/pubmed/36993983
http://dx.doi.org/10.3389/fimmu.2023.1133177

Ejemplares similares